| Outcome Measures: |
Primary: Maximum Observed concentration (Cmax) of Pimodivir, Cmax is the maximum observed concentration., Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6|Area Under Curve From Time of Dosing to the Time of the last Measurable Concentration (AUC[0-last]) of Pimodivir, AUC(0-last) is the AUC from time of dosing to the time of the last measurable (non-below quantification limit) concentration, calculated by linear-linear trapezoidal summation., Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6|AUC from time of dosing to infinity (AUC[0-infinity]) of Pimodivir, AUC(0-infinity) is the AUC from time of dosing to infinity, calculated as AUC(0-last) + Clast/ (lambda\[z\]), where Clast is the last observed measurable concentration and lambda(z) is the apparent terminal elimination rate constant., Predose (Day 1), 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96, and 120 hours postdose on Day 6 | Secondary: Number of Participants with Adverse Events as a Measure of Safety and Tolerability, An adverse event is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product., Up to 42 (+/-) 2 days
|
